Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

10.71
-0.0950-0.88%
Post-market: 10.960.2500+2.33%19:30 EDT
Volume:1.87M
Turnover:20.11M
Market Cap:950.77M
PE:-3.18
High:10.95
Open:10.90
Low:10.61
Close:10.81
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:1.01
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:19.63
PE(LYR):-3.37

Loading ...

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

GlobeNewswire
·
May 06

Kura Oncology to report first-quarter 2026 financial results after market close

Reuters
·
May 05

Kura Oncology grants 133,750 inducement stock options priced at $8.77 per share

Reuters
·
May 04

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 04

Kura Oncology, Kyowa Kirin dose first patient in Japan Phase 2 ziftomenib trial

Reuters
·
Apr 28

H.C. Wainwright Reaffirms Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Apr 20

Barclays Sticks to Their Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Apr 20

Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating

TIPRANKS
·
Apr 18

Sector Update: Health Care Stocks Higher Pre-Bell Friday

MT Newswires Live
·
Apr 17

BUZZ-Kura Oncology rises as kidney cancer combo shows early promise

Reuters
·
Apr 17

Kura says darlifarnib-cabozantinib trial posts 44% response rate in pretreated ccRCC

Reuters
·
Apr 17

Kura Oncology Inc - Reports Manageable Safety and Tolerability Profile in Rcc Patients

THOMSON REUTERS
·
Apr 17

Kura Oncology Inc - Treatment Durations Reached 56 Weeks; One-Third Remained on Therapy at Data Cut-off

THOMSON REUTERS
·
Apr 17

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

THOMSON REUTERS
·
Apr 17

Kura Oncology Initiated at Buy by Lake Street

Dow Jones
·
Apr 14

Kura Oncology announces annual shareholder meeting via webcast

Reuters
·
Apr 11

Kura Oncology to present FIT-001 darlifarnib-cabozantinib data in pretreated kidney cancer

Reuters
·
Apr 09

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

GlobeNewswire
·
Apr 09

Kura Oncology grants inducement stock options for 153,750 shares under 2023 plan

Reuters
·
Apr 03

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03